stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Current ratio
Ionis Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 7.9×, up 4.1× from fiscal 2025 (3.8×). Over the past ten years it has ranged from 3.6× (fiscal 2020) to 10.0× (fiscal 2019); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.8× | (54.83%) |
| FY2024 | 8.5× | 43.68% |
| FY2023 | 5.9× | (16.61%) |
| FY2022 | 7.1× | (27.48%) |
| FY2021 | 9.7× | 174.02% |
| FY2020 | 3.6× | (64.30%) |
| FY2019 | 10.0× | 26.51% |
| FY2018 | 7.9× | 64.19% |
| FY2017 | 4.8× | (19.56%) |
| FY2016 | 6.0× | 6.09% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 7.9× | 92.58% |
| Mar 2026 | 4.1× | 7.11% |
| Dec 2025 | 3.8× | 37.24% |
| Sep 2025 | 2.8× | (2.93%) |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ORKA Oruka Therapeutics, Inc. compare | 38.5× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 33.6× |
| CGON CG Oncology, Inc. compare | 22.2× |
| IONS Ionis Pharmaceuticals, Inc. | 7.9× |
| IMVT Immunovant, Inc. compare | 7.3× |
| KOD Kodiak Sciences Inc. compare | 2.5× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 2.1× |
| AXSM Axsome Therapeutics, Inc. compare | 1.4× |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.2× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement